AGN (Update)
Allergan Inc
Healthcare, Event Driven/Special Sit
08/22/2014
Presented
| Date | 08/19/2014 |
| Price | $223.08 |
| Market Cap | $59.00B |
| Ent Value | $66.99B |
| P/E Ratio | N/A |
| Book Value | $106.55 |
| Div Yield | N/A |
| Shares O/S | 264.26M |
| Ave Daily Vol | 2,140,000 |
| Short Int | 0.83% |
Current
| Price | $193.02 |
| Market Cap | $63.36B |
| Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey. |
Please note, this is an update to Long – Allergan plc (AGN), which was originally presented on November 6, 2013.
Publicly traded companies mentioned herein: Actavis plc (ACT), Allergan Inc (AGN), AstraZeneca PLC (AZN), Pfizer Inc (PFE), Valeant Pharmaceuticals (VRX)
Highlights
The presenter remains long shares of Actavis (ACT) and continues to view the risk/ reward profile as one of the best he sees in the market at this time. He now expects ACT to earn $20 per share in 2015 ($2 higher than his prior expectation), and also noted that downside risk to EPS (and the share price) based on his scenario analysis appears to be limited.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.